Phase 1 First in Human Study of ZN-d5 as a Single Agent

Key Inclusion Criteria:

NHL: relapsed or refractory NHL including DLBCL, FL, MZL, MCL, LCL, LPL and PTC

* Subjects must have received at least 2 prior lines of therapy and have either failed or not be eligible for any available therapies expected to provide clinical benefit and have measurable disease.

AML: Primary, secondary, or treatment-related AML, relapsed or refractory to prior therapy, which may include failure of one cycle of induction therapy.

* White blood cell count \< 25 × 109/L. Cytoreduction prior to treatment is acceptable.
* Subjects may not be pregnant and must agree to use an effective method of contraception.
* Eastern Cooperative Oncology Group performance status ≤ 2.
* Estimated life expectancy of at least 12 weeks.
* Adequate hematologic and organ function, including creatinine clearance ≥ 60 mL/min.

Key Exclusion Criteria:

* Recent interventions including major surgery, radiation therapy, stem cell transplant.
* Treatment with anti-neoplastic agents with 5 half-lives.
* Significant unresolved toxicity from prior treatments including active GVHD.
* Active central nervous system disease.
* Clinically substantial myocardial impairment.
* Prior therapy with venetoclax.